Table 1 Characteristics of the included studies

Alquraishi et al.

2020

2-arm RCT

10 wk

1. α-blocker

2. α-blocker + Desmopressin

22

29

4 wk

Chapple et al.

2009

2-arm RCT

4 wk

1. α-blocker

2. α-blocker + Tolterodine

323

329

12 wk

Ichihara et al.

2015

2-arm RCT

8 wk

1. α-blocker

2. α-blocker + Mirabegron

38

38

8 wk

Kakizaki et al.

2019

2-arm RCT

4 wk

1. α-blocker

2. α-blocker + Mirabegron

283

282

12 wk

Kaplan et al.

2020

2-arm RCT

4 wk

1. α-blocker

2. α-blocker + Mirabegron

339

337

12 wk

Kaplan et al.

2009

2-arm RCT

4 wk

1. α-blocker

2. α-blocker + Solifenacin

195

202

12 wk

Kaplan et al.

2012

2-arm RCT

6 wk

1. α-blocker

2. α-blocker + Fesoterodine

472

471

12 wk

Kim et al.

2017

2-arm RCT

8 wk

1. α-blocker

2. α-blocker + Desmopressin

39

47

8 wk

Konstantinidis et al.

2013

2-arm RCT

1 wk

1. α-blocker

2. α-blocker + Fesoterodine

23

24

4 wk

Kwon et al.

2020

2-arm RCT

8 wk

1. α-blocker

2. α-blocker + Mirabegron

19

39

8 wk

Nishizawa et al.

2011

3-arm RCT

8 wk

1. α-blocker

2. α-blocker + Propiverine (10 mg)

3. α-blocker + Propiverine (20 mg)

60

60

62

12 wk

Takeda et al.

2013

2-arm RCT

8 wk

1. α-blocker

2. α-blocker + Imidafenacin

154

154

12 wk

Yamaguchi et al.

2011

3-arm RCT

6 wk

1. α-blocker

2. α-blocker + Solifenacin (2.5 mg)

3. α-blocker + Solifenacin (5 mg)

212

210

203

12 wk

Yang et al.

2007

2-arm RCT

1 wk

1. α-blocker

2. α-blocker + Tolterodine

36

33

6 wk

Yokoyama et al.

2015

3-arm RCT

4 wk

1. α-blocker

2. α-blocker + Imidafencin (0.2 mg)

3. α-blocker + Imidafencin (0.1 mg)

46

43

41

8 wk